Skip to main content
Log in

Persistence with Cholinesterase Inhibitor Therapy for Dementia

An Observational Administrative Health Database Study

  • Original Research Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Objective

To determine if choice of drug and ease of administration affect persistence of therapy with Cholinesterase inhibitors (ChEIs) for treatment of dementia.

Methods

An observational administrative health database study was conducted in 5622 patients aged ≥65 years who received a new prescription for donepezil (DON), rivastigmine (RIV) or galantamine (GAL) from February to May 2006. Patients were followed for 1 year from initiation of therapy to determine percentage persistence and days of therapy. Once-daily galantamine extended release (GAL-ER) was compared with twice-daily galantamine immediate release (GAL-IR) to determine if ease of administration affected persistence. Previous treatment with ChEIs was also documented.

Results

One-year persistence rates were significantly different among the ChEIs: GAL-ER 54% (95% CI 51, 57), DON 46% (95% CI 43, 49) and RIV 40% (95% CI 37, 43). Average days of therapy were greater for GAL-ER (293) than for RIV (272), but there were no differences between DON (287) and GAL-ER or DON and RIV. One-year persistence was significantly greater for GAL-ER 54% (95% CI 48, 59) than for GAL-IR 44% (95% CI 39, 50), although there was no significant difference in days of therapy (293 vs 286, respectively). More patients currently treated with RIV (40.5%) or GAL-ER (32.3%) had received previous treatment with a different ChEI than with DON (21.9%).

Conclusion

Among possible factors affecting persistence of ChEI therapy for dementia, choice of drug, ease of administration and previous treatment appear to be important.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I

Similar content being viewed by others

References

  1. Canadian Study of Health and Aging Working Group. Canadian study of health and aging: study methods and prevalence of dementia. Can Med Assoc J 1994; 150: 899–913

    Google Scholar 

  2. Thompson S, Lanctot KL, Herrmann N. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer’s disease. Expert Opin Drug Saf 2004; 3: 425–40

    Article  PubMed  CAS  Google Scholar 

  3. Hogan DB, Bailey P, Carswell A, et al. Management of mild to moderate Alzheimer’s disease and dementia. Alzheimers Dement 2007; 3: 355–84

    Article  PubMed  CAS  Google Scholar 

  4. Herrmann N, Gauthier S, Lysy P. Clinical practice guidelines for severe Alzheimer’s disease. Alzheimers Dement 2007; 3: 385–97

    Article  PubMed  Google Scholar 

  5. Mauskopf JA, Paramore C, Lee WC, et al. Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings. J Manag Care Pharm 2005; 11: 231–51

    PubMed  Google Scholar 

  6. Suh DC, Thomas SK, Valiyeva E, et al. Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer’s disease. Drugs Aging 2005; 22: 695–707

    Article  PubMed  CAS  Google Scholar 

  7. Dybicz SB, Keohane DJ, Erwin WG, et al. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis. Am J Geriatr Pharmacother 2006; 4: 154–60

    Article  PubMed  Google Scholar 

  8. Sicras-Mainar A, Vergara J, Leon-Colombo T, et al. Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer’s disease patients treated with donepezil, rivastigmine, galantamine and memantine. Rev Neurol 2006; 43: 449–53

    PubMed  CAS  Google Scholar 

  9. Herrmann N, Gill SS, Bell CM, et al. A population-based study of cholinesterase inhibitor use for dementia. J Am Geriatr Soc 2007; 55: 1517–23

    Article  PubMed  Google Scholar 

  10. Seltzer B. Is long-term treatment of Alzheimer’s disease with cholinesterase inhibitor therapy justified? Drugs Aging 2007; 24: 881–90

    Article  PubMed  CAS  Google Scholar 

  11. Francis PT, Nordberg A, Arnold SE. A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer’s disease? Trends Pharmacol Sci 2005; 26: 104–11

    Article  PubMed  CAS  Google Scholar 

  12. AD 2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD 2000): randomised double-blind trial. Lancet 2004; 363: 2105–15

    Article  Google Scholar 

  13. Fillit H, Hill J. Economics of dementia and pharmacoeconomics of dementia therapy. Am J Geriatr Pharmacother 2005; 3: 39–49

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This study was funded by Janssen-Ortho Inc., who paid for the data acquisition and statistical analysis. Nathan Herrmann has received honoraria, consultation fees and/or research support from Janssen-Ortho Inc., Pfizer Canada Inc., Novartis Pharmaceuticals Canada Inc. and Lundbeck. William Dalziel has received honoraria and consultation fees from Janssen-Ortho Inc., Pfizer Canada Inc. and Novartis Pharmaceuticals Canada Inc. Carin Binder and Steve Smyth are employees of Janssen-Ortho Inc. Fernando Camacho is a consultant with Damos Inc.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Nathan Herrmann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Herrmann, N., Binder, C., Dalziel, W. et al. Persistence with Cholinesterase Inhibitor Therapy for Dementia. Drugs Aging 26, 403–407 (2009). https://doi.org/10.2165/00002512-200926050-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200926050-00004

Keywords

Navigation